Morbidity and mortality of the Russian population from acute respiratory viral infections, pneumonia and vaccination

In order to assess the impact of influenza vaccination and pneumococcal infection (PI) were studied seasonal morbidity and mortality because of influenza, acute respiratory viral infections (ARVI) and pneumonia among the population of the Russian Federation during 2012-2016 timeframe. The methods. There were analyzed the data of Federal service for surveillance in consumer rights protection and human welfare (Rospotrebnadzor) on influenza vaccination and PI and ARVI morbidity (including influenza), diseases of the respiratory system (DRS). The information on mortality of the population of Russia because of these diseases received from official publications of the Federal State statistics service (Rosstat) and The Ministry of health of the Russian Federation (Ministry of Health of Russia) on the mortality rates of the population of Russia because of these illnesses. Results: the analysis revealed that compared to 2015, in 2016 the incidence rate of ARVI in total Russian population was increased to 5,7%. The incidence rate of influenza in 2016 reached 60,5 cases per 100 thousand of the total population and was higher than the 1,8 times than in 2015 (34,01 on 100 thousand people). The incidence rate of pneumonia in total population was increased by 24,0% in 2016 compared to 2015. According to Rosstat data, the increase of deaths because of influenza and ARVI was mainly in the first semester of 2016, which was associated with influenza epidemic. Mortality because of pneumonia dropped by 10,8% and from other DRS – by 6,9%, which might indicate on the improvement of the quality of medical care and prevention of DRS. Reduction in the mortality rate because of pneumonia also was due to significant influenza vaccination coverage and the increasing number of children and adults vaccinated against PI

Вакцинопрофилактика пневмококковых инфекций у взрослых. Резолюция совета экспертов (Москва, 16 декабря 2017 г.)

The following key issues of pneumococcal infection prophylaxis were discussed during the expert council: incidence rates of community-acquired pneumococcal pneumonia and other pneumococcal infections, local epidemiological data, increases in antimicrobial resistance and pneumococcal serotypes substitution, current international and Russian clinical guidelines, practical approaches, and pneumococcal vaccination coverage of adult population in the Russian Federation. The agreement between the experts about a need to distinguish the use of conjugate vaccines and polysaccharide vaccines in different subpopulations has been achieved.В ходе совета экспертов обсуждены ключевые вопросы профилактики пневмококковой инфекции (ПИ): ситуация с заболеваемостью внебольничной пневмококковой пневмонией (ВП) и другими ПИ, особенности локальной эпидемиологии, роста резистентности и замещения штаммов пневмококка, существующие международные и российские клинические рекомендации, текущие практические подходы, охват вакцинацией взрослого населения РФ. Сформулировано консолидированное мнение о необходимости разграничения использования конъюгированных и полисахаридных вакцин в разных группах населения

Вакцинопрофилактика пневмококковых инфекций у взрослых. Резолюция совета экспертов (Москва, 16 декабря 2017 г.)

The following key issues of pneumococcal infection prophylaxis were discussed during the expert council: incidence rates of community-acquired pneumococcal pneumonia and other pneumococcal infections, local epidemiological data, increases in antimicrobial resistance and pneumococcal serotypes substitution, current international and Russian clinical guidelines, practical approaches, and pneumococcal vaccination coverage of adult population in the Russian Federation. The agreement between the experts about a need to distinguish the use of conjugate vaccines and polysaccharide vaccines in different subpopulations has been achieved.В ходе совета экспертов обсуждены ключевые вопросы профилактики пневмококковой инфекции (ПИ): ситуация с заболеваемостью внебольничной пневмококковой пневмонией (ВП) и другими ПИ, особенности локальной эпидемиологии, роста резистентности и замещения штаммов пневмококка, существующие международные и российские клинические рекомендации, текущие практические подходы, охват вакцинацией взрослого населения РФ. Сформулировано консолидированное мнение о необходимости разграничения использования конъюгированных и полисахаридных вакцин в разных группах населения